Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 23, 2024CancersOpen Access

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

EBEvangelia BogatsaGLGeorge LazaridisCSChrysoula Stivanaki

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bogatsa et al. (2024) studied this question.

synapsesocial.com/papers/68e6de7cb6db64358765a91chttps://doi.org/10.3390/cancers16091619
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer2024 · 380 citations
  2. 2Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse2022 · 9 citations
  3. 3Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the US2021 · 805 citations
  4. 4A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients2014 · 132 citations